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A B S T R A C T
The 24-hour urine is golden standard for metabolic assessment of stone formers. However, due to the difficulties in
collecting almost 1/3 of the samples can not be used for the analysis. Therefore, we analyzed first morning urine and cal-
culated different risk indexes in order to asses possibility of using it in determining urolithiasis risk. Subjects were di-
vided into 4 groups: male patients (n=31, age 18–64), female patients (n=31, age 25–63), male controls (n=16, age
25–64) and female controls (n=19, age 21–65). First morning urine pH, concentrations of calcium, magnesium, phos-
phate, sodium, potassium, chloride, citrate, urate, oxalate, creatinine and glycosaminoglycans were determined. Based
on them, ionic concentrations and activity products of calcium oxalate and phosphate were calculated by EQUIL 2. In
addition, different risk indices were calculated. The results showed that both patients and control groups had metabolic
disorders, but the frequencies of occurrence were statistically independent. Significant difference in concentration of uri-
nary constituents between corresponding patient and control groups was observed only for glycosaminoglycans in female
subjects. Ca/Cit ratio and Baggio index could differentiate between both corresponding patients and control groups. The
results indicate that interplay between stone formation inhibitors and promotors is responsible for urinary stone forma-
tion and that the first morning urine could be used in assessing urolithiasis risk and its prevention.
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Introduction
Urolithiasis, the disease of urinary stone formation, is
a pathological state in which stones are formed in differ-
ent parts of the kidney and urinary tract. Due to the
problems associated with it, such as nephrocalcinosis, ob-
struction of kidneys, loss of kidney tissue and function,
haematuria, infection and pain caused by passing stones,
the patients often need hospital care1.
Urolithiasis is present in the whole world, but its oc-
currence and frequency depends on genetical, nutritive
and ecological factors. Urinary stones appear in 0.1–0.5%
of world population in a given year, with relapse rate of
about 80%. It was established that 12% of males and 5%
of females will suffer from urolithiasis until they reach
age 70. Urinary stones are equally frequent in both kid-
neys, with 40% of patients having them bilateraly. Most
of kidney stones appear between age 20 and 40, which
makes urolithiasis a serious medical and socio-economi-
cal problem2.
In the last thirty years, our understanding of the pro-
cesses leading to urinary stone formation has increased
significantly. Urinary stones are formed when urine be-
comes supersaturated. The initial step is formation of
the nucleus, followed by the growth of crystals. Condi-
tions leading to crystal growth are not necessarily the
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same as the ones leading to the formation of nucleus3. It
is obvious that numerous components of urine can influ-
ence different phases of stone formation. Of special inter-
est, for urolithiasis prevention and treatment, are small
molecules (pyrophosphate, citrate) and macromolecules
(glycosaminoglycans, Tamm-Horsfall glycoprotein, uro-
pontine, nephrocalcine) acting as inhibitors of crystal
growth and/or crystal aggregation.
Understanding urine composition process enabled us
to apply specific diagnostics and specific treatments for
most urolithiasis patients4,5. In addition, various anti-re-
lapse drugs and easier and less invasive operative proce-
dures become avalaible6.
In numerous studies of urinary composition disor-
ders, the 24-hour urine is used as golden standard. How-
ever, there are several problems connected with its col-
lection and preservation. Collecting these samples is
time demanding and unreliable. The first common error
in collecting the 24-hour urine is obtaining the wrong
volume, resulting in a wrong assessment of daily voiding
of the urine components constituting urinary stones. In
addition, during collection of 24-hour urine it is neces-
sary to add different additives, in order to prevent precip-
itation of particles and bacterial growth. These additives
can destroy or change the structure of urinary compo-
nents, and therefore lead to incorrect results in the as-
sessment of the crystallization characteristics of urine7.
These problems lead to the rejection of almost one third
of the samples. Therefore, reliability of urines collected
in different time intervals (first morning urine, 8h urine
and 16h urine) in evaluating stone formers has been and
is still investigated7–9. It was shown that 8h and 16h
urines collected during night and day, respectively, are
reliable specimens for determinating metabolic abnor-
malities7. A significant correlation between calcium, oxa-
late (Ox), citrate (Cit) and magnesium concentrations de-
termined in early spot urine and 24-h urine was shown9,
but the role of the glycosaminoglycans (GAG) in calcium
oxalate kidney stone formation remains unclear10. Dis-
pute about which urine (24 hours, first morning) should
be used when assessing the risk of urinary stone forma-
tion is ongoing.
In this paper, we tried to assess possibility of using
first morning urine in determining urolithiasis risk in
patients with recurrent calcium oxalate urolithiasis from
Eastern Croatia, with aim to facilitate targeted treatment
of the patients and prevention of urinary stone formation.
Materials and Methods
Subjects were divided into 4 groups: male patients
(n=31, age 18–64), female patients (n=31, age 25–63),
male controls (n=16, age 25–64) and female controls
(n=19, age 21–65). Subjects were assigned to patient or
control groups according to their medical history. Groups
of patients were comprised of subjects with recurrent cal-
cium oxalate urolithiassis, while control groups were
comprised of subjects without medical history of stone
formation or renal diseases. All subjects had given in-
formed consent to participate in the study. The study was
approved by Ethics Committee of Medical faculty, Osijek.
The first morning urine was used for analysis. pH was
measured immediately with pH-meter (Radiometer Co-
penhagen). Presence of the crystals was determined by
optical microscopy (Olympus CX40). Urine sediment was
obtained by centrifugation and treatment of urine by
Urised system (Cronolab). Obtained sediment was then
checked for the presence of the crystals. All urines were
tested by Combur 10 test M (Roche) for possible organ
damages.
The first morning urine without the added preserva-
tives was used for biochemical analysis. Concentrations
of sodium, potassium, calcium, magnesium, chloride, in-
organic phosphate, urate, oxalate, citrate and creatinine
were determined immediately. Part of urine was sepa-
rated, centrifuged and put in the refrigerator at –20oC for
total GAG determination.
Calcium, magnesium and phosphate urinary concen-
trations were determined spectrophotometrically by Olym-
pus test kits: calcium concentration was determined by
o-cresolphthalein-complexon method11, magnesium con-
centration was determined by Xylidyl blue method12,
phosphate concentration was determined by UV molyb-
date method13.
Sodium and potassium concentration were determi-
ned by flame photometry (Flame photometer IL943).
Chloride concentration were determined by coulome-
tric titration (CTM3 chloride titrator, Radiometer Co-
penhagen).
Urate and creatinine concentrations were determined
by Roche test kits: urate by uricase PAP method14 and
creatinine by enzymatic PAP method15 using Olympus
AU400 analyzer.
Citrate concentration was determined by Boehringer
Mannheim test kit16, oxalate concentration was deter-
mined by Sigma Diagnostic test kit17 and total GAG con-
centration by carbazole method18.
Obtained concentrations of determined urinary consti-
tuents were compared with reference values (Table 119,20)
to determine existence of the metabolic disorders.
Chemical compositions of the stones were determined
by IR, using KBr pellets on Perkin Elmer spectropho-
tometer model 882.
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TABLE 1
BOUNDARY VALUES OF URINARY CONSTITUENTS CONCEN-
TRATIONS FOR DETERMINING METABOLIC DISORDERS19,20
Metabolic disorder







Urinary ionic concentration and activity products of
calcium oxalate and brushite, defined as:
IAP(CaOx)=a(Ca2+)´a(Ox2–) (1)
IAP(brushite) = a(Ca2+)´a(HPO42–) (2)
were calculated by the computer program EQUIL 221 for
each subject based on results of the first morning urine
analysis. EQUIL 2 doesn’t include GAG.
Based on calculated ionic concentrations Ca/Cit and
Ca/Mg ratios were calculated, as well as three different
indices: Tisselius risk index (RI), Ogawa index and Baggio
index (BI).
Tisselius risk index, which uses creatinine (Cr) con-
centrations instead of urine volume, is defined as22:
RI=(Ca/Cr)0.71 · (Ox/Cr) · (Mg/Cr)–0.24 · (Cit/Cr)–0.10 (3)
where Ca, Ox, Mg and Cit concentrations are expressed
in mmol/L and Cr in mol/L.
Ogawa index, AP(CaOx)EQ2, is defined as23, 24:
AP(CaOx)EQ2=6.838x10–5 · [Ca]0.78 · [Mg]–0.30 ·
[Ox]0.91 · [Cit]–0.17 (4)
where concentrations are expressed in mmol/L.
Baggio index (BI) is defined as25:
BI=(Ox/Cit) · GAG · 104 (4)
where concentrations are expressed in mmol/L.
Statistics
Results of the urine analysis are given per g of crea-
tinine and expressed as mean±standard deviation (SD).
All data were tested for the normality of distribution.
When data were not normally distributed, square root or
log transformations were applied for ensuring normality.
One way ANOVA was used to determine differences be-
tween groups (in all cases variances were homogeneous).
Mean differences were separated by Tukey test. For
nominal data (stone composition, crystalluria, metabolic
disorders) contingency analysis was used (please note
that null hypothesis for this analysis is that the data are
coming from independent populations, therefore p>0.05
means that the data are significantly different). The level
of significance was set at p<0.05. All analyses were per-
formed using statistical for software SAS 9.1 or JMP 6.0.
Results and Discussion
Stones composition
Urolithiasis is a special form of biomineralization26.
Its frequency increased during 20th century, especially in
industrially developed countries. This led to increased in-
terest in elucidating processes and mechanisms involved
in urinary stone formation, especially calcium urolithi-
asis, compromising about 80% of stones mainly calcium
oxalates, and rarely calcium phosphates6.
Composition of the stones of both male and female pa-
tients in this study is given in Table 2. All patients had
calcium-oxalate stones, pure or mixed with hydroxya-
patite. Contingency analysis showed that there is a statis-
tically significant difference in stone composition be-
tween male and female patients (p>0.327).
Many previous studies have shown that, pure or mix-
ed, calcium oxalates are the most frequent constituents
of urinary calculi (50–86%, e.g.27,28). When comparing
urtolithiasis data for Croatia with those for some devel-
oped European countries (France, Germany) no signifi-
cant difference can be observed27.
Crystalluria
The formation of the stones, especially calcium ones,
is a complex process depending on many factors. Basic
condition for calcium stone formation is urine supersa-
turation with calcium oxalate or calcium phosphate, or
both, which can lead to precipitation of one or more solid
phases. However, urine of majority of persons is usually
found in upper concentration part of metastable region
where nucleation usually happens and where presence of
promotors induces precipitation at even lower activity
product than usual8. Therefore, crystalluria can be often
found in persons who do not form stones, making its
prognosis value controversial29. In addition, crystalluria
is often not correlated with metabolic disorders, which
can be explained by retention of the crystals at tubular
level or strong inhibitory effect of the macromolecules on
stone formation30.
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TABLE 2
COMPOSITION AND FREQUENCY OF OCCURANCE OF URINARY
STONES IN MALE AND FEMALE PATIENTS
Stone type





COM, COD 5/31 3/31
COM, HAP 8/31 7/31
COD, HAP 2/31 –
COM, COD, HAP 1/31 –
COM – calcium oxalate monohydrate, COD – calcium oxalate di-
hydrate, HAP – hydroxyapatite
TABLE 3
FREQUENCY OF THE CRYSTALLURIA (NUMBER OF SUBJECTS
WITH DIFFERENT TYPES OF CRYSTALLURIA / TOTAL NUMBER
OF PATIENTS OR CONTROLS) IN PATIENTS AND CONTROLS




no crystals 48/62 29/35
CaOx – calcium oxalate, CaP – calcium phosphate, H2U – uric acid
Occurrence of crystalluria in investigated groups is
given in Table 3. Three types of crystals have been de-
tected, calcium oxalate, calcium phosphate and uric acid.
Higher frequency of crystalluria in patients in compari-
son with controls has been observed. Contingency analy-
sis showed that this difference is statistically significant
(p>0.258). Earlier studies have shown that in addition to
higher crystalluria occurrence rate in patients, formed
crystals are also larger8. Robertson31 has shown that in
the urine of the stone formers bigger aggregated calcium
oxalate dihydrate (COD) crystals can be found, while in
the urine of the non-stone formers smaller calcium oxa-
late monohydrate (COM) crystals can be found.
Urine composition
The precise identification of abnormal excretion of
metabolic risk factors is at the basis of any method for
preventing urinary stone formation7. Therefore, the first
step in investigating urolithiasis is determination of urine
composition. Average values of first morning urine meta-
bolic parameters for the investigated groups are given in
Table 4.
In investigated groups 64% of male and 65% of female
subjects had urine pH lower than 6, which is in accord
with data from earlier study where there was 70% of
such subjects7.
Comparison of the concentrations of other parame-
ters showed that statistically significant difference in
concentration of calcium (p>0.017), urate (p>0.027), ci-
trate (p>0.001) and GAG (p>0.002) exist between differ-
ent groups. However, only significant difference between
corresponding patients and control groups were found
for GAG concentration in female subjects.
Both male and female patients had higher, although
not statistically different, urinary calcium concentration
than respective control groups. This agrees with earlier
findings that stone formers have higher average first
morning urinary calcium concentrations than non-stone
formers32, indicating the significant promoter role of cal-
cium in stone formation.
In contrast, both male and female patients had lower,
although not statistically different, urinary citrate con-
centration than respective controls. Both female patients
and control had higher citrate concentrations than corre-
sponding groups of male subjects. This agrees with liter-
ature data32 and points to the significant inhibitory role
of citrate, more expressed with female subjects.
The highest urate content has been detected in urine
of female patients. Urate content in urine of male pa-
tients was significantly lower than the one in urine of fe-
male patients, while urate content in urine of both con-
trol groups was not significantly different from values
obtained in patients groups.
The highest GAG content was detected in female con-
trols. This value was significantly higher than the ones
obtained for male and female patients. The value ob-
tained for male controls was not significantly different
from the ones obtained in all other groups. This finding
points to a possible inhibitory role of GAG, which is in ac-
cordance with some of earlier results. GAGs are present
at apical surface of tubular kidney cells33, in that way in-
hibiting and preventing crystal adhesion to kidney cells,
which is an important step in urolithiasis34,35. Damage of
GAGs layer may result in increased retention of CaOx
crystals36. However, there are contradictory data. This is
a consequence of significantly different role that differ-
ent GAGs have in different stages of stone formation10,37.
Comparison of the other parameters, revealed no sig-
nificant differences. In general, all concentrations were
higher in female subjects, which could be explained by
the lower creatinine amount that females excrete in
urine due to smaller muscular mass. Other literature
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TABLE 4
AVERAGE CONCENTRATION OF THE FIRST MORNING URINE CONSTITUENTS (MEAN ± SD) FOR MALE AND FEMALE PATIENTS AND




Male Female Male Female
pH 5.85±0.72 5.82±0.61 6.11±0.81 5.95±0.73 0.554NS
Sodium (mmol/g cr) 115.7±52.6 148.1±61.8 117.6±74.2 135.6±65.1 0.173NS
Potassium (mmol/g cr) 37.9±17.1 45.8±16.3 40.7±20.6 49.6±32.9 0.367NS
Chloride (mmol/g cr) 132.0±55.8 162.5±76.4 128.5±77.6 150.0±82.3 0.387NS
Calcium (mmol/g cr) 3.92±2.41A,B 4.45±2.74A 2.66±1.53B 2.98±1.66A,B 0.0178
Magnesium (mmol/g cr) 2.77±0.91 2.95±1.08 2.47±1.07 3.37±1.34 0.112NS
Phosphate (mmol/g cr) 14.07±5.25 15.04±5.47 16.20±9.77 16.81±6.28 0.474NS
Urate (mmol/g cr) 2.31±0.76B 2.82±0.76A 2.36±0.74A,B 2.74±0.72A,B 0.028
Oxalate (mmol/g cr) 0.22±0.08 0.24±0.12 0.18±0.09 0.19±0.11 0.103NS
Citrate (mmol/g cr) 1.59±0.90B 2.44±0.99A 2.20±0.91A,B 3.16±1.17A <0.001
Glycosaminoglycans (mg/g cr) 4.16±2.02B 4.85±2.05B 5.70±1.69A,B 6.59±2.85A 0.002
NS – Not statistically different
data confirm that these parameters have a smaller influ-
ence on urinary stone formation32.
Metabolic disorders
Urine analysis showed that both patients and control
groups (both male and female) have metabolic disorders
(Table 5, boundary values after ref.19,20). Contingency
analysis showed that the values obtained for control
groups and patients, for both male (p>0.269) and female
(p>0.504), are significantly different. Significant differ-
ences were also observed between male and female con-
trols (p>0.264) and patients (p>0.188). These findings
agree with earlier studies38,39.
Hypercalciuria is the most frequent disorder observed
in both male and female patients. Hyperoxaluria and
hyperuricosuria were also detected in high frequencies.
These three stone promoting factors have been deter-
mined in 27 of 47 males and 30 of 50 females, similar to
other studies. Hypocitraturia has been found in higher
frequency than in other studies38.
These results indicate that the risk of urinary stone
formations cannot be evaluated based on a single meta-
bolic parameter.
Risk indices
In order to assess the risk of urinary stone formation
as precisely as possible, different risk indices have been
defined. Indices used in this investigation are described
in Materials and methods section, and results are pre-
sented in Table 6.
Although there are statistically significantly differ-
ences between the values of all indices between different
groups, only Ca/Cit and BI can distinguish between both
female and male patients and controls, while Ca/Mg and
Tisselius index can distinguish only between female pa-
tient and controls. None of indices can distinguish be-
tween male and female patients and/or male and female
control groups.
Statistically significant differences in Ca/Cit ratio be-
tween corresponding patients and control groups indi-
cate equilibrium disorder in favor of promoting factors,
which leads to increased supersaturation and lowered in-
hibitory urine potential.
Although there are statistically significantly differ-
ences between the values of all indices between different
groups, only Ca/Cit and BI can distinguish between both
female and male patients and controls, while Ca/Mg and
Tisselius index can distinguish only between female pa-
tient and controls. None of indices can distinguish be-
tween male and female patients and/or male and female
control groups.
Statistically significant differences in Ca/Cit ratio be-
tween corresponding patients and control groups indi-
cate equilibrium disorder in favor of promoting factors,
which leads to increased supersaturation and lowered in-
hibitory urine potential.
Ca/Mg ratio was significantly higher for female pa-
tients in comparison with control group, and also higher
(but not significantly) for male patients in comparison
with control groups. Similarly to Ca/Cit ratio this also indi-
cates equilibrium disorder in favor of promoting factors.
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TABLE 5
FREQUENCY OF METABOLIC DISORDERS (NUMBER OF SUBJECTS WITH DIFFERENT TYPES OF METABOLIC DISORDER / TOTAL
NUMBER OF MALE OR FEMALE CONTROLS OR PATIENTS) IN MALE AND FEMALE SUBJECTS
Metabolic disorder
Male Female
Controls Patients Controls Patients
HCa 4/31 1/19 5/31
HOx 1/16 2/31 1/19
HU 2/16 2/31 1/19
hCit 6/31 2/19 4/31
hMg 2/19 2/31
HCa, HOx 2/16 2/19
HCa, HU 1/31
HCa, hCit 1/31 1/31
HOx, hCit 1/31 1/31
HOx, HU 1/31 1/19 2/31
hCit, hMg 1/16 2/31 1/19 4/31
HCa, HOx, HU 2/31
HCa, HU, hCit 1/31
HU, HOx, hCit 1/31
none 8/16 11/31 8/19 8/31
HCa – hypercalciuria, HOx – hyperoxaluria, HU – hyperuricosuria, hCit – hypocitraturia, hMg – hypomagnesiuria
IAP (COM) and Ogawa index are higher, but not sig-
nificantly, for patients than for corresponding control
groups. This is in accordance with previous studies22,24,
and also indicates higher patients urine supersaturation.
Female patients had statistically higher RI than con-
trol groups. Male patients also had higher values, but not
significantly higher. This is in accordance with earlier
studies22.
Baggio index was significantly higher in both patient
groups than in corresponding control groups. Literature
data show that over 80% of stone formers can be distin-
guished from nonstone formers using this index. In addi-
tion it enables the use of fasting urine and avoids the
problems connected with 24-urine collection and diet
restrictions25.
Correlation between IAP (COM) and risk indices
The IAP (COM) values were correlated with other in-
dices for each group of the subjects. Significant correla-
tions were established with Ogawa index for all groups,
Tiselius index for all but male patients, Ca/Cit and Ca/Mg
ratios for both control groups and Baggio index for fe-
male control groups (Table 7).
Pearson coefficient is a measure of linear correlation
of the variables. Therefore, from a purely statistical
point of view, lack of significant correlation between IAP
(COM) and Baggio index for patient and male control
groups, Ca/Cit and Ca/Mg ratio for patient groups, is a
little bit surprising, because all those indices contain one
common variable, calcium or oxalate concentration. In
this respect, lack of significant correlation would be more
easily expected for Tisselius and Ogawa indices, because
they are not linear in calcium and oxalate concentrations.
These observations point to the importance of the in-
terplay between promoting and inhibiting urinary con-
stituents in kidney stone formation. Therefore several
methods for the determination of the urinary inhibitory
activity to CaOx precipitation40–42 and calcium binding
capacity43 have already been proposed, and used40 in the
follow up of patients with recurrent urolithiasis44.
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TABLE 6
UROLITHIASIS RISK INDICES (X±SD) FOR PATIENT AND CONTROL GROUPS (MALE AND FEMALE). VALUES IN THE SAME ROW WITH




Male Female Male Female
Ca/Cit 3.135±2.784A 2.317±2.233A,B 1.504±1.209B,C 1.142±0.872C < 0.001
Ca/Mg 1.399±0.623A 1.546±0.81A 1.179±0.714A,B 0.917±0.501B 0.001
IAP(COM) ´ 10–8 1.979±1.310A 1.521±0.809A,B 1.471±1.092A,B 1.000±0.944B 0.008
Ogawa index ´ 10–8 0.892±0.556A 0.739±0.423A,B 0.816±0.559A,B 0.461±0.383B 0.014
Tiselius index 491.7±246.4A,B 567.7±406.4A 331.2±253.6A,B 375.8±305.7B 0.006
Baggio index 731.3±847.1A 404.0±379.1A 162.4±164.8B 186.0±210.9B < 0.001
IAP – ionic activity product
TABLE 7
PEARSON CORRELATION COEFFICIENTS AND PROBABILITIES FOR THE CORRELATION OF CALCIUM OXALATE MONOHYDRATE













































NS – Not statistically different
Conclusion
In order to successfully deal with problems connected
with urinary stone formation it is of utmost importance
to be able to differentiate between possible stone formers
and non-stone formers. Although 24-hours urine is con-
sidered to be golden standard in this sense, problems
connected with its collection render its applicability. The
results of this study are yet another support in qualifying
first morning urine as easily collectable and valuable
specimen for stone former discrimination. However, more
investigations on lager number of subjects are needed,
because results are pointing to a redefinition of risk indi-
ces for first morning urine in order for it to be success-
fully applied. Correct first morning urine risk indices
would also facilitate targeted treatment of the patients
enabling better prevention of urinary stone formation.
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METABOLI^KI I FIZIKALNO-KEMIJSKI PARAMETRI UROLITIJAZE
U PRVOM JUTARNJEM URINU
S A @ E T A K
24-satni urin je »zlatni standard« za metaboli~ku procjenu stvaranja kamenaca. Me|utim, s obzirom na pote{ko}e
prilikom sakupljanja urina, gotovo 1/3 uzoraka ne mo`e se koristiti za analize. Zbog toga smo analizirali prvi jutarnji
urin i ra~unali razli~ite indekse rizika, s namjerom da uka`emo na mogu}nost njegove upotrebe u odre|ivanju rizika
urolitijaze. Ispitanici su bili podijeljeni u 4 skupine: mu{karci (n=31, dobi 18–64 godine), `ene (n=31, dobi 25–63 go-
dine), mu{ka kontrolna skupina (n=16, dobi 25–64 godine) i `enska kontrolna skupina (n=9, dobi 21–65 godina). U
prvom jutarnjem urinu odre|eni su pH, koncentracije kalcija, magnezija, fosfata, natrija, kalija, klorida, citrata, urata,
oksalata, kreatinina i glikozaminoglikana. Temeljem ovih podataka ra~unalnim programom EQUIL 2 izra~unate su
ionske koncentracije i aktivni produkti kalcijeva oksalata i fosfata, a dodatno su izra~unati i razli~iti indeksi rizika.
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Rezultati su pokazali da skupine bolesnika, kao i kontrolne skupine, imaju metaboli~ke poreme}aje, ali u~estalost po-
jave je statisti~ki neovisna. Zna~ajna razlika u koncentracijama mokra}nih parametara izme|u odgovaraju}ih skupina
bolesnika i kontrolnih skupina ustanovljena je samo za glikozaminoglikane u `ena. Odnos Ca/Cit i Baggio indeks mogu
razlikovati skupinu bolesnika od kontrolne skupine. Me|usobno djelovanje inhibitora i promotora stvaranja kamenaca
mo`e biti odgovorno za nastajanje kamenaca a prvi jutarnji urin mo`e se koristiti u odre|ivanju rizika od urolitijaze i
prilikom njene prevencije.
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